Amplia Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Amplia Therapeutics has a total shareholder equity of A$11.4M and total debt of A$1.5M, which brings its debt-to-equity ratio to 13.1%. Its total assets and total liabilities are A$14.8M and A$3.4M respectively.

Belangrijke informatie

13.1%

Verhouding schuld/eigen vermogen

AU$1.49m

Schuld

Rente dekkingsratio	n/a
Contant	AU$3.39m
Aandelen	AU$11.42m
Totaal verplichtingen	AU$3.43m
Totaal activa	AU$14.85m

Recente financiële gezondheidsupdates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Recent updates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Feb 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Analyse van de financiële positie

Kortlopende schulden: ATX's short term assets (A$6.8M) exceed its short term liabilities (A$3.4M).

Langlopende schulden: ATX's short term assets (A$6.8M) exceed its long term liabilities (A$23.4K).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ATX has more cash than its total debt.

Schuld verminderen: ATX's debt to equity ratio has increased from 0% to 13.1% over the past 5 years.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ATX has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.

Voorspelling contante baan: ATX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.

Amplia Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.9 million.

Amplia Therapeutics Limited, Annual General Meeting, Aug 23, 2024

New minor risk - Shareholder dilution

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

New major risk - Market cap size

Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US

New major risk - Financial position

New major risk - Market cap size

Amplia Therapeutics Limited Announces Chief Financial Officer Changes

New major risk - Market cap size

New major risk - Market cap size

Amplia Therapeutics Limited, Annual General Meeting, Aug 24, 2023

Amplia Receives Grant to Collaborate with CSIRO

Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945

Amplia Therapeutics Limited Appoints Christopher Burns as Managing Director, Effective December 5, 2022

Amplia Therapeutics Limited Announces CEO Changes

Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer

Amplia Therapeutics Limited, Annual General Meeting, Aug 25, 2022

Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis

Amplia Therapeutics Limited Receives Second Ethics Clearance for Phase 2 Trial

Amplia Therapeutics Limited Receives Human Research Ethics Committee Approval to Initiate Phase 2 Clinical Trial of Its Focal Adhesion Kinase Inhibitor, AMP945

Amplia Therapeutics Limited Completes Manufacture of AMP945 for Planned Trials

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$104k worth of stock

Chief Financial Officer Jeff Carter has left the company

Amplia to Conduct Phase 2 Trial in First-Line Pancreatic Cancer Patients

Non-Executive Director recently bought AU$122k worth of stock

Amplia Therapeutics Limited Announces Results from Successful Phase 1 Clinical Trial of Amp945

Amplia Therapeutics Limited Receives New Data from its Collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research, Sydney

Amplia Therapeutics Limited announced that it expects to receive AUD 3.81455 million in funding from Platinum Investment Management Limited, Blueflag Holdings Pty Ltd, Acorn Capital Limited, and other investors

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Completes Single Dose Study of AMP945

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Amplia Therapeutics Limited Initiates Multiple Dose Study of AMP945

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

New 90-day high: AU$0.22

Amplia Therapeutics Limited Announces First Human Dose in Phase 1 Clinical Trial of AMP945

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.987791 million.

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven